S*BIO Advances JAK2 Inhibitor SB1518 Into Phase 1/2 Clinical Trial In Australia For The Treatment Of Chronic Idiopathic Myelofibrosis S*BIO Pte Ltd announced the initiation of a Phase 1/2 clinical trial of SB1518, a potent and orally-active JAK2 inhibitor, in leading medical centers in Australia for patients with chronic idiopathic myelofibrosis (CIMF). The trial is designed to evaluate the safety and tolerability of SB1518 in patients with CIMF and is expected to enrol up to 50 patients.
Source: www.medicalnewstoday.comTorreyPines' NGX426, An Oral AMPA/Kainate Receptor Antagonist, Meets Primary Endpoints In Reducing Capsaicin Induced Pain In Healthy Subjects TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) announced that oral administration of NGX426, an AMPA/kainate-type glutamate receptor antagonist, demonstrated a statistically significant reduction in spontaneous pain, hyperalgesia (abnormally increased pain state) and allodynia (pain resulting from normally non-painful stimuli to the skin) compared to placebo following intradermal injections of capsaicin in a human experimental model of cutaneous pain, hyperalgesia and allodynia.
Source: www.medicalnewstoday.comAdvocates Energized By Expected Appointment Of Clinton To Secretary Of State Position Women's rights and human rights advocates are "energized" by the expected appointment of Sen. Hillary Clinton (D-N.Y.) to the secretary of state position and hope she will bring a "dramatic new focus" to women's issues worldwide, the Boston Globe reports.
Source: www.medicalnewstoday.comFDA Approves Duramed's Synthetic Conjugated Estrogens A Vaginal Cream Barr Pharmaceuticals, Inc. (NYSE: BRL) announced that the U.S. Food and Drug Administration (FDA) has approved its subsidiary Duramed Pharmaceuticals, Inc.'s New Drug Application (NDA) for Synthetic Conjugated Estrogens-A (SCE-A) 0.625 mg/g Vaginal Cream. SCE-A Vaginal Cream is a plant-derived local estrogen product indicated for the treatment of moderate to severe vaginal dryness and pain with intercourse, both of which are symptoms of vulvar and vaginal atrophy due to menopause.
Source: www.medicalnewstoday.comVical Receives Milestone Payment From Merck & Co., Inc. Triggered By Planned Initiation Of Investigational Cancer DNA Vaccine Trial Vical Incorporated (Nasdaq: VICL) announced the receipt of a $1.0 million milestone payment from Merck & Co., Inc. based on Merck's planned initiation of a Phase I clinical trial of an investigational plasmid DNA (pDNA) cancer vaccine. The candidate vaccine is based on Vical's DNA gene delivery technology and encodes human telomerase reverse transcriptase (hTERT). hTERT is the subject of separate license agreement.
Source: www.medicalnewstoday.comGeoVax's Phase 2a HIV/AIDS Vaccine Human Trials To Begin In North And South America GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), an Atlanta-based biotechnology company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents, announced today that the launch of its Phase 2a Human Vaccine Trials will take place in twelve sites across North and South America. These trials are conducted in collaboration with The National Institutes of
Health (NIH), and the HIV Vaccine Trials Network (HVTN).
Source: www.medicalnewstoday.comViroPharma Submits Supplemental Biologics License Application For Cinryze(TM) To Treat Acute Attacks Of Hereditary Angioedema ViroPharma Incorporated (Nasdaq: VPHM) announced that the company submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for Cinryze(TM) C1 Inhibitor (human) as a treatment for acute attacks of hereditary angioedema (HAE). The sBLA is based on a re-analysis and resubmission of data from a pivotal Phase 3 acute treatment study of Cinryze and interim data from an ongoing open label acute study of the drug.
Source: www.medicalnewstoday.com109 Medicines And Vaccines Now In Development For HIV/AIDS America's pharmaceutical research companies are testing 109
medicines and vaccines to treat or prevent HIV/AIDS and related conditions, according to a report released today by the Pharmaceutical Research and Manufacturers of America (PhRMA). December 1 marks the 20th anniversary of "World AIDS Day" - a global awareness campaign that originated at the 1988 World Summit of Ministers of
Health on Programmes for AIDS Prevention.
Source: www.medicalnewstoday.comUSA Today Examines No-Cost Prescription Drug Samples USA Today on Monday examined how no-cost
prescription drug samples can influence physicians' prescribing habits and how
health systems across the U.S. are beginning to ban or limit the samples. According to a study published in September in the Southern Medical Journal, more than 90% of U.S.
Source: www.medicalnewstoday.comNew Citeline Analysis Finds Substantial Disparity In The Number Of Ongoing Clinical Trials For The Top 20 Biotech Companies Biotech is reclaiming its buzzword status once again, and Citeline authors Christine Blazynski and Tracy DeGregorio look at the top 20 biotech companies in the December issue of GCPj and find significant disparity between the top five companies and the rest of the set. In fact, the top three companies, Genentech, Amgen and Celgene cumulatively account for 50% of the total number of ongoing trials for this set of 20 companies.
Source: www.medicalnewstoday.com
# posted by Network @ 8:00 PM
